Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
HKCeND has developed a robust blood test for early diagnosis, staging, and monitoring of Alzheimer’s disease; an AI-driven scoring system to predict AD risk; and a novel brain-wide genome editing therapeutic approach. The center has also established the first comprehensive Chinese AD genetic database through whole genome sequencing studies. These advances have not yet reached late-stage clinical trials but represent significant progress in translational research toward new diagnostics and therapies
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hong Kong Center for Neurodegenerative Diseases.